Cite

HARVARD Citation

    von Tresckow, B. et al. (2019). Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma. Leukemia & lymphoma. 60 (11), pp. 2705-2711. [Online]. 
  
Back to record